Journal of Pharmacy and Pharmacology · 1987 · 37 citations · 13 references
MedicinePharmacologyExperimental PharmacologyNeuropharmacologyPharmacodynamicsCardiac MedicationsCardiovascular PharmacodynamicsCardiovascular PharmacologyDopaminergic PharmacologyHemodynamic PharmacologyRenal PharmacologyAfterload ChangesBeta-adrenergic AgentsBlood PressureCardiovascular Drug PharmacologyGanglionic BlockersPeripheral VasodilationRenal Vascular ResistanceVascular Resistance
The study examined the receptor pharmacology of dopexamine hydrochloride’s cardiovascular effects in anaesthetized dogs administered intravenously. Dopexamine hydrochloride increases cardiac output, contractility, and heart rate through β2‑adrenoceptor activation; it raises renal blood flow by reducing vascular resistance via DA1 receptors, induces peripheral vasodilation through combined DA1, DA2, and β2 stimulation, and its β2 agonist action also lowers afterload, indicating potential use in acute heart failure.
The receptor pharmacology of the cardiovascular effects of dopexamine hydrochloride in the anaesthetized dog (given by i.v. infusion of 3 X 10(-9)-10(-7) mol kg-1 min-1) has been analysed by the use of selective receptor antagonists and of ganglionic blockade. The increases in cardiac output, contractility, and rate were antagonized by the beta 2-adrenoceptor antagonist, ICI 118551. Renal blood flow rose secondary to reduction in renal vascular resistance and this was antagonized by SCH 23390, a highly selective DA1-receptor antagonist. Peripheral vasodilation and reduction of blood pressure were mediated by a combination of DA1- and DA2-receptor and beta 2-adrenoceptor stimulation. In a separate group of dogs, the cardiac stimulant effects of dopexamine HCl were partially reflex and were reduced by ganglion block, revealing responses due to stimulation of cardiac beta 2-adrenoceptors. Thus the beta 2-adrenoceptor agonist action of dopexamine HCl is not only partly responsible for afterload reduction but also leads to direct cardiac stimulation. From its cardiovascular profile, dopexamine HCl is likely to be of use in acute treatment of heart failure.
13
Regional Distribution of β-Adrenoceptors in the Human Heart
Otto‐Erich Brodde, Stephan Schüler, Roland Kretsch et al. · Journal of Cardiovascular Pharmacology · 1986 · 182 citations